Compare Ascendis Pharma A/S (ASND) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243.46 (market cap $45.15B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 2.5× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| ASND | TTWO | |
|---|---|---|
Market Cap | $17.74B | $45.15B |
Sector | Health | Media |
52-Week High | $277.18 | $262.29 |
52-Week Low | $163.32 | $189.69 |
Enterprise Value | $18.11B | $46.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Take-Two Interactive (TTWO) trades at $243.20, down 1.18% on the day, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, including Q1 2026 EPS of $0.80 versus $0.563 expected, and benefits from positive sentiment around Grand Theft Auto VI pre-orders. However, fundamentals reveal challenges with a net income margin of -4.48% and negative ROE of -10.56%, though revenue grew to $5.63B in 2025. Cash flow improved with net cash flow of $457.20M in 2025, driven by financing activities.
The outlook is optimistic due to GTA VI's upcoming launch, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, with debt-to-asset ratio at 39.87% in 2025, and reliance on blockbuster game success. Institutional sentiment is strongly bullish, with 79% of analysts rating Buy, but investors should monitor execution on profitability targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
